| Previous Close | 3.25 |
| Open | 3.25 |
| Bid | 3.00 x 200 |
| Ask | 3.60 x 1800 |
| Day's Range | 3.03 - 3.25 |
| 52 Week Range | 3.03 - 7.57 |
| Volume | 62,945 |
| Avg. Volume | 130,910 |
| Market Cap | 161.07M |
| Beta | 2.03 |
| PE Ratio (TTM) | -5.08 |
| EPS (TTM) | -0.62 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
- PR Newswire•12 days ago
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany. The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.
- ACCESSWIRE•15 days ago
Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
- Associated Press•17 days ago
Compugen reports 2Q loss
The Holon, Israel-based company said it had a loss of 18 cents per share. The company's shares closed at $3.80. A year ago, they were trading at $6.91. _____ This story was generated by Automated Insights ...
